AP NEWS

Male Hypogonadism - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 28, 2018

DUBLIN--(BUSINESS WIRE)--Sep 28, 2018--The “Male Hypogonadism - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Male Hypogonadism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 4, 5, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Male Hypogonadism - Overview Male Hypogonadism - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Male Hypogonadism - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Male Hypogonadism - Companies Involved in Therapeutics Development Antares Pharma Inc Clarus Therapeutics Inc Diurnal Group Plc EndoCeutics Inc Ferring International Center SA Lipocine Inc M et P Pharma AG Medlab Clinical Ltd Merck & Co Inc Mereo Biopharma Group Plc Repros Therapeutics Inc TesoRx Pharma LLC Viramal Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nnbkm5/male_hypogonadism?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005665/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL CONSUMER MEN

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/28/2018 06:16 PM/DISC: 09/28/2018 06:16 PM

http://www.businesswire.com/news/home/20180928005665/en

AP RADIO
Update hourly